Clinical Trial Update: Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial evaluating fenofibrate and metformin to improve insulin sensitivity in Type 2 diabetes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• FENOFIBRATE (Fenofibrate)
• metformin (metformin)

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Type 2 Diabetes, Dyslipidemia | Phase 2, Phase 3 | Status: TERMINATED